Skip to main content
Publications

Combining rituximab with mycophenolate for the treatment of interstitial lung disease

By 29 Aprile 2024Maggio 7th, 2024No Comments

Combining rituximab with mycophenolate for the treatment of interstitial lung disease

Conflict of interest statement
Conflict of interest: E.R. Volkmann is supported by the National Heart, Lung, and Blood Institute (grant number K23 HL150237) and reports the following financial relationships outside of the submitted work on autoimmune-associated ILD: consulting for Boehringer Ingelheim, Roche, CSL Behring and GSK, speaking for Boehringer Ingelheim, and institutional support received for performing studies in systemic sclerosis for Kadmon, Forbius, Boehringer Ingelheim, Horizon and Prometheus.

Discover more